Central Texas Clinical Research, LLC

Austin, Texas 78705

1 studies enrolling now · 12 studies all time

What they study most

COVID-19, Cardiovascular Disease, Dyslipidemia, HIV-1 Infection, Hepatitis C, Chronic, High Cardiovascular Risk, Migraine Disorders, Migraine With or Without Aura, Moderately to Severely Active Crohn Disease, Obesity, Overweight, Type 2 Diabetes

Studies at this site

• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• ABTECT - Maintenance — Running, not enrolling
• Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV — Running, not enrolling
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed